Key Highlights

  • Merck reported quarterly revenue of $16.4 billion, representing 5% year-over-year growth.
  • Keytruda generated $8.4 billion in sales and remains the central driver of oncology revenue.
  • Vaccine sales declined due to weaker demand for Gardasil in China and Japan.
  • New products, including WinRevair and O2Ver are beginning to contribute to meaningful growth.
  • Management outlined a $70 billion pipeline opportunity targeting commercialization by the mid-2030s.

Introduction: Merck Navigates the Post-Keytruda Investment Cycle

Merck stands at a pivotal moment in its corporate trajectory. For more than a decade, the company’s growth story has been anchored by Keytruda, a blockbuster immunotherapy that transformed cancer treatment and generated tens of billions of dollars in revenue. However, with the drug’s patent protection expected to expire later in the decade, investors are increasingly focused on the company’s next phase of growth.

The company’s latest quarterly results highlight both the strength of its current portfolio and the strategic investments being made to sustain long-term expansion. Revenue growth remains steady, supported by continued demand for oncology treatments and emerging contributions from newly launched therapies.

At the same time, Merck is reshaping its product portfolio through acquisitions, late-stage clinical development programs, and expansion into new therapeutic areas such as cardiometabolic disease, infectious disease prevention, and pulmonary medicine.

Management argues that these efforts could support more than $70 billion in potential commercial opportunity by the mid-2030s, positioning the company to sustain growth even after the eventual loss of exclusivity for Keytruda.

Pharmaceutical Sector Analysis: Innovation Cycles and Patent Risks

The global pharmaceutical industry is defined by cycles of innovation and patent expiration. Breakthrough drugs can generate extraordinary revenue streams, but the loss of exclusivity eventually invites generic competition that rapidly erodes pricing power.

For large pharmaceutical companies, maintaining long term growth requires a continuous pipeline of new therapies capable of replacing declining blockbuster revenues. This dynamic has intensified in recent years as regulatory scrutiny, pricing pressures, and geopolitical factors reshaping healthcare markets.

Merck’s situation illustrates this challenge clearly. Keytruda has become one of the most successful oncology drugs in history, with broad use across multiple tumor types including lung cancer, melanoma, and bladder cancer. However, patent protection is expected to expire around 2028, potentially exposing the drug to biosimilar competition.

At the same time, the pharmaceutical sector is experiencing a wave of scientific innovation. Advances in immunotherapy, antibody drug conjugates, gene therapy, and targeted molecular treatments are expanding the range of treatable diseases.

Companies that can translate these breakthroughs into commercially successful therapies stand to capture significant market share.

Merck’s strategy reflects this environment. The company is investing heavily in a diversified pipeline across oncology, infectious disease, cardiometabolic conditions, and immunology.

Merck Earnings Outlook: Core Revenue Drivers

Merck reported total revenue of $16.4 billion for the quarter, representing 5% growth compared with the previous year. Excluding foreign exchange impacts, revenue increased by approximately 4%.

Oncology remains the company’s largest business segment. Sales of the Keytruda family of products reached $8.4 billion, rising 5% year over year. Demand was driven primarily by increased use in earlier stage cancers and continued adoption across metastatic indications.

The company recently launched a subcutaneous version of the drug known as Keytruda QLEX. Early sales totaled $35 million during the quarter. Management expects adoption to accelerate after the implementation of a permanent reimbursement code in the United States.

Beyond Keytruda, Merck’s oncology portfolio includes several emerging therapies. Wellrec, a treatment for advanced renal cell carcinoma, recorded sales of $220 million with growth of 37%. Uptake was particularly strong in the United States as physicians expanded its use among previously treated patients.

In vaccines, performance was more uneven. Gardasil generated $1 billion in revenue but declined 35% compared with the previous year due to weaker demand in China and Japan. Outside those markets, international sales grew modestly and U.S. sales increased primarily due to pricing adjustments.

Merck also continues to expand in respiratory and cardiometabolic treatments. WinRevair, a therapy for pulmonary arterial hypertension, generated global sales of $467 million during the quarter. More than 1,500 new patients in the United States began treatment during the period.

Another recent addition to the portfolio is O2Ver, a chronic obstructive pulmonary disease therapy acquired through the purchase of Verona Pharma. The drug generated $178 million in sales as prescriber adoption expanded across the United States.

The company’s animal health division also contributed steady growth. Segment revenue increased 6%, supported by strong demand in livestock health products.

Financial Performance and Market Trends

Merck’s profitability remains robust despite the costs associated with acquisitions and research investment. The company reported a gross margin of 79.7%, representing a decline of approximately 1.1 percentage points compared with the previous year.

The margin contraction was attributed largely to higher inventory reserves. However, favorable product mix provided partial offset.

Operating expenses totaled $6.8 billion on a non-GAAP basis. Excluding charges related to business development transactions, operating costs remained broadly stable as increased research investment was balanced by operational efficiency initiatives.

The company reported non-GAAP earnings per share of $2.04 for the quarter.

Looking ahead, Merck expects full year 2026 revenue to fall within a range of $65.5 billion to $67 billion, representing growth of approximately 1% to 3%.

This modest outlook reflects several headwinds. Management estimates that generic competition, pricing reforms under the U.S. Inflation Reduction Act, and contractual changes related to certain products could reduce revenue by roughly $2.5 billion.

Gross margin for the full year is projected to reach approximately 82%.

Operating expenses are expected to increase significantly due to a one-time $9 billion charge related to the acquisition of Sidera Therapeutics.

Investment Strategy: Building the Post-Keytruda Portfolio

A central question for investors is how Merck will sustain growth once Keytruda loses exclusivity. Management has outlined a strategy built on new product launches, late-stage pipeline development, and targeted acquisitions.

The acquisition of Sidera Therapeutics represents one example of this approach. The deal adds MK1406, a long-acting antiviral candidate designed to prevent influenza infection in high-risk individuals. Early clinical data suggests the therapy could generate more than $5 billion in annual revenue if successful.

Merck is also advancing several promising clinical programs across multiple therapeutic areas.

One of the most closely watched is enlicitide, an oral PCSK9 inhibitor designed to reduce LDL cholesterol levels. Phase III trial results demonstrated sustained reductions in cholesterol markers, highlighting the potential for a convenient alternative to injectable therapies.

The company is also expanding its presence in HIV treatment. Recent Phase III data showed that a two-drug regimen combining doravirine and islatravir achieved efficacy comparable to standard three drug therapies. The regimen may offer new treatment flexibility for patients while reducing long term medication burden.

Management believes that more than twenty pipeline programs could become meaningful growth drivers in the coming decade. Ten of these candidates may reach significant clinical milestones within the next two years.

Strategic Outlook: A Diversified Growth Model

Merck’s long term growth strategy rests on diversification across therapeutic areas and product categories.

Oncology will remain a central pillar of the company’s portfolio, particularly as Keytruda continues to expand into additional cancer indications. However, management is actively developing new oncology therapies including antibody drug conjugates and targeted cancer treatments.

Infectious disease prevention represents another area of opportunity. Vaccines and antiviral therapies remain essential components of global healthcare systems, particularly as emerging pathogens and seasonal outbreaks continue to pose risks.

Meanwhile, cardiometabolic and respiratory diseases represent large and growing markets. Therapies targeting cholesterol reduction, pulmonary hypertension, and chronic respiratory conditions could provide substantial revenue opportunities.

The company also expects significant expansion in its animal health business, which management believes could more than double in size by the mid-2030s.

Taken together, these initiatives form the foundation of a diversified growth model designed to reduce reliance on any single blockbuster therapy.

Conclusion

Merck’s latest results demonstrate the enduring strength of its oncology franchise while also highlighting the strategic transition underway within the company.

Keytruda continues to generate extraordinary revenue, but management is investing aggressively to build the next generation of growth drivers. Through pipeline innovation, targeted acquisitions, and expansion into new therapeutic areas, the company aims to establish a portfolio capable of sustaining growth well beyond the Keytruda patent cycle.

For investors, the coming years will likely be defined by the pace at which these emerging therapies move from clinical development into commercial success. If Merck’s pipeline delivers on its potential, the company could enter the next decade with a broader and more resilient revenue base.

FAQ

Why is Keytruda so important to Merck’s business?

Keytruda is Merck’s leading oncology therapy and one of the highest revenue generating cancer drugs globally. It is approved for multiple cancer types and contributed more than half of the company’s pharmaceutical revenue during the quarter.

What risks does Merck face from Keytruda patent expiration?

Keytruda’s patent protection is expected to expire around 2028, potentially allowing biosimilar competitors to enter the market. This could significantly reduce pricing power and revenue, making pipeline development critical for sustaining growth.

How significant is Merck’s pipeline opportunity?

Merck estimates its pipeline represents approximately $70 billion in potential commercial opportunity by the mid 2030s. More than twenty programs are in late stage development or recently launched, with several expected to deliver major clinical milestones in the next two years.

What is the strategic importance of the Sidera acquisition?

The Sidera acquisition adds MK1406, a long acting antiviral therapy designed to prevent influenza infection in high risk populations. The drug could generate more than $5 billion in annual revenue if approved, strengthening Merck’s infectious disease portfolio.

How does Merck plan to diversify its revenue sources?

Merck is expanding beyond oncology through investments in cardiometabolic treatments, infectious disease therapies, vaccines, and animal health products. This diversification strategy aims to reduce reliance on any single blockbuster drug while supporting long term revenue growth.